Literature DB >> 26527289

Amphiregulin Is a Critical Downstream Effector of Estrogen Signaling in ERα-Positive Breast Cancer.

Esther A Peterson1, Edmund C Jenkins1, Kristopher A Lofgren2, Natasha Chandiramani1, Hui Liu1, Evelyn Aranda1, Maryia Barnett1, Paraic A Kenny3.   

Abstract

Estrogen stimulation promotes epithelial cell proliferation in estrogen receptor (ERα)-positive breast cancer. Many ERα target genes have been enumerated, but the identities of the key effectors mediating the estrogen signal remain obscure. During mouse mammary gland development, the estrogen growth factor receptor (EGFR) ligand amphiregulin acts as an important stage-specific effector of estrogen signaling. In this study, we investigated the role of amphiregulin in breast cancer cell proliferation using human tissue samples and tumor xenografts in mice. Amphiregulin was enriched in ERα-positive human breast tumor cells and required for estrogen-dependent growth of MCF7 tumor xenografts. Furthermore, amphiregulin levels were suppressed in patients treated with endocrine therapy. Suppression of EGF receptor signaling appeared necessary for the therapeutic response in this setting. Our findings implicate amphiregulin as a critical mediator of the estrogen response in ERα-positive breast cancer, emphasizing the importance of EGF receptor signaling in breast tumor pathogenesis and therapeutic response. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26527289      PMCID: PMC4651747          DOI: 10.1158/0008-5472.CAN-15-0709

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  Genome-wide analysis of estrogen receptor binding sites.

Authors:  Jason S Carroll; Clifford A Meyer; Jun Song; Wei Li; Timothy R Geistlinger; Jérôme Eeckhoute; Alexander S Brodsky; Erika Krasnickas Keeton; Kirsten C Fertuck; Giles F Hall; Qianben Wang; Stefan Bekiranov; Victor Sementchenko; Edward A Fox; Pamela A Silver; Thomas R Gingeras; X Shirley Liu; Myles Brown
Journal:  Nat Genet       Date:  2006-10-01       Impact factor: 38.330

2.  Local Epidermal Growth Factor Production in Women with Endometriosis.

Authors:  Natalia Yu. Sotnikova; Yulia S. Antsiferova; Maria N. Shokhina
Journal:  Russ J Immunol       Date:  2001-04

3.  Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.

Authors:  Massimo Cristofanilli; Vicente Valero; Aroop Mangalik; Melanie Royce; Ian Rabinowitz; Francis P Arena; Joan F Kroener; Elizabeth Curcio; Claire Watkins; Sarah Bacus; Elsa M Cora; Elizabeth Anderson; Patrick J Magill
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

4.  Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.

Authors:  M J Ellis; A Coop; B Singh; L Mauriac; A Llombert-Cussac; F Jänicke; W R Miller; D B Evans; M Dugan; C Brady; E Quebe-Fehling; M Borgs
Journal:  J Clin Oncol       Date:  2001-09-15       Impact factor: 44.544

5.  Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.

Authors:  Andreas Polychronis; H Dudley Sinnett; Dimitri Hadjiminas; Hemant Singhal; Janine L Mansi; Dharsha Shivapatham; Sami Shousha; Jie Jiang; David Peston; Nigel Barrett; David Vigushin; Ken Morrison; Emma Beresford; Simak Ali; Martin J Slade; R Charles Coombes
Journal:  Lancet Oncol       Date:  2005-06       Impact factor: 41.316

6.  Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland.

Authors:  Sonia Mallepell; Andrée Krust; Pierre Chambon; Cathrin Brisken
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-01       Impact factor: 11.205

7.  17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells.

Authors:  L Altucci; R Addeo; L Cicatiello; S Dauvois; M G Parker; M Truss; M Beato; V Sica; F Bresciani; A Weisz
Journal:  Oncogene       Date:  1996-06-06       Impact factor: 9.867

8.  ERalpha-CITED1 co-regulated genes expressed during pubertal mammary gland development: implications for breast cancer prognosis.

Authors:  J McBryan; J Howlin; P A Kenny; T Shioda; F Martin
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

9.  The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study.

Authors:  Eleanor Gutteridge; Amit Agrawal; Robert Nicholson; Kwok Leung Cheung; John Robertson; Julia Gee
Journal:  Int J Cancer       Date:  2010-04-15       Impact factor: 7.396

Review 10.  RSK in tumorigenesis: connections to steroid signaling.

Authors:  T S Karin Eisinger-Mathason; Josefa Andrade; Deborah A Lannigan
Journal:  Steroids       Date:  2010-01-04       Impact factor: 2.668

View more
  20 in total

1.  Amphiregulin regulates proliferation and migration of HER2-positive breast cancer cells.

Authors:  Hannah Schmucker; Walker M Blanding; Julia M Mook; Jessica F Wade; Jang Pyo Park; Kerri Kwist; Hiral Shah; Brian W Booth
Journal:  Cell Oncol (Dordr)       Date:  2017-11-27       Impact factor: 6.730

2.  Amphiregulin as a Novel Serum Marker of Puberty in Girls.

Authors:  Frank M Biro; Susan M Pinney; Richard C Schwartz; Bin Huang; Ashley M Cattran; Sandra Z Haslam
Journal:  J Pediatr Adolesc Gynecol       Date:  2017-02-16       Impact factor: 1.814

3.  The Role of Fgf Signaling on Epithelial Cell Differentiation in Mouse Vagina.

Authors:  Y U Hirano; Kentaro Suzuki; Taisen Iguchi; Gen Yamada; Shinichi Miyagawa
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

4.  Exogenous ERα Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice.

Authors:  Lisette M Cornelissen; Linda Henneman; Anne Paulien Drenth; Eva Schut; Roebi de Bruijn; Sjoerd Klarenbeek; Wilbert Zwart; Jos Jonkers
Journal:  J Mammary Gland Biol Neoplasia       Date:  2019-11-15       Impact factor: 2.673

5.  In vivo reprogramming of non-mammary cells to an epithelial cell fate is independent of amphiregulin signaling.

Authors:  Andrea L George; Corinne A Boulanger; Lisa H Anderson; Stéphanie Cagnet; Cathrin Brisken; Gilbert H Smith
Journal:  J Cell Sci       Date:  2017-04-28       Impact factor: 5.285

6.  Inter-Individual Variation in Response to Estrogen in Human Breast Explants.

Authors:  Karen A Dunphy; Amye L Black; Amy L Roberts; Aman Sharma; Zida Li; Sneha Suresh; Eva P Browne; Kathleen F Arcaro; Jennifer Ser-Dolansky; Carol Bigelow; Melissa A Troester; Sallie S Schneider; Grace Makari-Judson; Giovanna M Crisi; D Joseph Jerry
Journal:  J Mammary Gland Biol Neoplasia       Date:  2020-03-09       Impact factor: 2.673

7.  Amphiregulin retains ERα expression in acquired aromatase inhibitor resistant breast cancer cells.

Authors:  Yuanzhong Wang; Yen-Dun Tony Tzeng; Gregory Chang; Xiaoqiang Wang; Shiuan Chen
Journal:  Endocr Relat Cancer       Date:  2020-12       Impact factor: 5.678

8.  FOXC1 is associated with estrogen receptor alpha and affects sensitivity of tamoxifen treatment in breast cancer.

Authors:  Jinhua Wang; Yali Xu; Li Li; Lin Wang; Ru Yao; Qiang Sun; Guanhua Du
Journal:  Cancer Med       Date:  2016-12-28       Impact factor: 4.452

9.  Role of Cytochrome P450 (CYP)1A in Hyperoxic Lung Injury: Analysis of the Transcriptome and Proteome.

Authors:  Krithika Lingappan; Suman Maity; Weiwu Jiang; Lihua Wang; Xanthi Couroucli; Alex Veith; Guodong Zhou; Cristian Coarfa; Bhagavatula Moorthy
Journal:  Sci Rep       Date:  2017-04-04       Impact factor: 4.379

10.  Parathyroid Hormone-Related Protein Negatively Regulates Tumor Cell Dormancy Genes in a PTHR1/Cyclic AMP-Independent Manner.

Authors:  Rachelle W Johnson; Yao Sun; Patricia W M Ho; Audrey S M Chan; Jasmine A Johnson; Nathan J Pavlos; Natalie A Sims; T John Martin
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-16       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.